Marengo Therapeutics

Marengo Therapeutics company information, Employees & Contact Information

Explore related pages

Marengo Therapeutics email format Marengo Therapeutics management contacts

Related company profiles:

Marengo Therapeutics, a clinical stage biotech company, is pioneering an entirely new way to activate the body’s own immune system to mount a rapid, effective, and durable response against cancer. Our unique therapeutic platform selectively boosts T cells, turbocharging potent anti-tumor activity and promoting long-term immunity to keep cancer at bay. For more information visit our website (https://www.marengotx.com)

Company Details

Employees
46
Address
840 Memorial Drive,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
https://www.marengotx.com
Keywords
Immuno-oncology, Oncology, T cell biology, Immunology, Drug Development, Biologics.
HQ
Cambridge, MA
Competitors
QLD Biotherapeutics Inc, Incendia Therapeutics, ODDITY LABS, Scismic, Nona Biosciences, Manifold Bio, Stellaromics Inc., Pledge Therapeutics, Kytopen, 1910 Genetics.
Looking for a particular Marengo Therapeutics employee's phone or email?

Marengo Therapeutics Questions

News

Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board - PR Newswire

Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board PR Newswire

Marengo Therapeutics Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune Diseases - PR Newswire

Marengo Therapeutics Enters Multi-Year Collaboration With University of Pennsylvania Institute for Immunology and Immune Health to Advance Next Wave Precision T Cell Immunology Research in Oncology and Autoimmune Diseases PR Newswire

Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025 - Yahoo Finance

Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025 Yahoo Finance

Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4 - Eastern Progress

Marengo Therapeutics to Present Key Pipeline Updates at 2025 SITC Annual Meeting and Reveal First Asset from TriSTAR™ Platform Targeting Nectin-4 Eastern Progress

Ipsen and Marengo Therapeutics announce second strategic - GlobeNewswire

Ipsen and Marengo Therapeutics announce second strategic GlobeNewswire

Marengo to Present a Late-breaking Clinical Oral Abstract at ESMO 2025 on Initial Phase 2 Clinical Data of Invikafusp Monotherapy Activity in Patients with Antigen-Rich Solid Tumors Resistant to Immune Checkpoint Blockade - The AI Journal

Marengo to Present a Late-breaking Clinical Oral Abstract at ESMO 2025 on Initial Phase 2 Clinical Data of Invikafusp Monotherapy Activity in Patients with Antigen-Rich Solid Tumors Resistant to Immune Checkpoint Blockade The AI Journal

Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at ESMO 2025 - Eastern Progress

Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at ESMO 2025 Eastern Progress

Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen - PR Newswire

Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen PR Newswire

Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform - PR Newswire

Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform PR Newswire

Companies like Marengo Therapeutics

Scismic logo - Similar company to Marengo Therapeutics

Scismic

19
Stellaromics Inc. logo - Similar company to Marengo Therapeutics

Stellaromics Inc.

49
Pledge Therapeutics logo - Similar company to Marengo Therapeutics

Pledge Therapeutics

23
1910 Genetics logo - Similar company to Marengo Therapeutics

1910 Genetics

32
Manifold Bio logo - Similar company to Marengo Therapeutics

Manifold Bio

47
Incendia Therapeutics logo - Similar company to Marengo Therapeutics

Incendia Therapeutics

37
ODDITY LABS logo - Similar company to Marengo Therapeutics

Oddity Labs

42
Nona Biosciences logo - Similar company to Marengo Therapeutics

Nona Biosciences

61
Kytopen logo - Similar company to Marengo Therapeutics

Kytopen

34
QLD Biotherapeutics Inc logo - Similar company to Marengo Therapeutics

Qld Biotherapeutics Inc

25

Top Marengo Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant